ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interactions of Paroxetine. Safety and efficacy of trimipramine pharmacotherapy for women who are breast-feeding and their neonates and infants have not been established. Avoid prescribing trimipramine pharmacotherapy to women who are breast-feeding. Trimipramine appears to produce its antidepressant action primarily by potentiating the CNS biogenic amines, specifically norepinephrine and serotonin, by blocking their re-uptake at the presynaptic nerve terminals. Trimipramine is absorbed from the GI tract following oral ingestion and generally achieves peak blood concentrations within 2 hours. Concurrent alcohol use may increase the CNS depressant action of trimipramine. Trimipramine pharmacotherapy has been associated with bone marrow depression, cardiac dysrhythmias, confusion, dry mouth, GI complaints, postural hypotension, and skin rash.
